In Vivo

Rebuilding Big Pharma's business model

The blockbuster business model that underpinned Big Pharma's success is now irreparably broken. The industry needs a new approach.

By James Gilbert, Preston Henske and Ashish Singh

The blockbuster business model that underpinned Big Pharma's success is now irreparably broken. The industry needs a new approach.

Published in November 2003

I want to talk to your experts in: Please select an industry from the dropdown list

We work with ambitious leaders who want to define the future, not hide from it. Together, we achieve extraordinary outcomes.

Your email Please enter a valid email address